.gif "IP Gear")
Elvia1023
Featured Member / Supp Guru / Board Supporter
Featured Member
Kilo Klub Member
Registered
Board Supporter
Verified Customer
- Joined
- Feb 27, 2008
- Messages
- 26,708
I partly agree with you. For me yes that is a lot of adrol. In fact I think it is more than enough for everyone. I think the most effective (highest) dose of adrol should be about 100mg if people want the most benefits whilst avoiding many of the bad side effects. Granted some get bad side effects even with just 50mg per day. Below is a study indicating the little difference in returns but increased side effects when using 100mg or 150mg. Although in the grand scheme of things 150mg is not a huge dose of adrol. You do realize it is commonly used at much higher doses. I have seen studies done with higher doses for months at a time. Granted it's usually on HIV or Anemia patients but the logic should still apply. Adrol is often given to HIV patients for 30+ weeks (see the 2nd study) and is considered relatively safe as long as blood values (liver and cholesterol etc) are monitored.
I have experimented a lot with it and think 50-100mg is best for me. But there are loads of bodybuilders out there using 150mg+ for long periods. So yes 150mg is a big dose but compared to many it's not huge by any means. I would never recommend it but that's a different subject.
Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting.
Hengge UR1, Stocks K, Wiehler H, Faulkner S, Esser S, Lorenz C, Jentzen W, Hengge D, Goos M, Dudley RE, Ringham G.
BACKGROUND:
Despite highly active antiretroviral therapy (HAART), chronic involuntary weight loss still remains a serious problem in the care of HIV patients. Various alterations in energy metabolism and endocrine regulation have been found to cause loss of lean body mass (LBM) and body cell mass (BCM). Previous studies in HIV-positive men undergoing androgen replacement therapy or treatment with recombinant growth hormone (rGH) have shown partial restoration of LBM, but these treatments have largely been ineffective in eugonadal individuals.
STUDY DESIGN:
Double-blind, randomized, placebo-controlled trial of 89 HIV-positive women and men with wasting assigned to the anabolic steroid oxymetholone [50 mg twice (BID) or three times daily (TID)] or placebo for 16 weeks followed by open-label treatment. STUDY ENDPOINTS: Body weight, bioimpedance measurements, quality of life parameters and appetite.
RESULTS:
Oxymetholone led to a significant weight gain of 3.0 +/- 0.5 and 3.5 +/- 0.7 kg in the TID and BID groups, respectively (P < 0.05 for each treatment versus placebo), whereas individuals in the placebo group gained an average of 1.0 +/- 0.7 kg. Body cell mass increased in the oxymetholone BID group (3.8 +/- 0.4 kg; P < 0.0001) and in the oxymetholone TID group (2.1 +/- 0.6 kg; P < 0.005), corresponding to 12.4 and 7.4% of baseline BCM, respectively. Significant improvements were noted in appetite and food intake, increased well-being and reduced weakness by self-examination. The most important adverse event was liver-associated toxicity. Overall, 35% of patients in the TID, 27% of patients in the BID oxymetholone group and no patients in the placebo group had a greater than five times baseline increase for alanine aminotransferase during the double-blind phase of the study.
CONCLUSIONS:
Oxymetholone can be considered an effective anabolic steroid in eugonadal male and female patients with AIDS-associated wasting. The BID (100 mg/day) regimen appeared to be equally effective as the TID (150 mg/day) regimen in terms of weight gain, LBM and BCM and was associated with less, but still significant liver toxicity.
PMID: 12646793 DOI: 10.1097/01.aids.0000050853.71999.16
Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection.
Hengge UR1, Baumann M, Maleba R, Brockmeyer NH, Goos M.
The effect of the testosterone derivative oxymetholone alone or in combination with the H1-receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor alpha (TNF alpha), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30-week prospective pilot study. Thirty patients were randomly assigned to either oxymetholone monotherapy (n 14) or oxymetholone plus ketotifen (n 16). Patients receiving treatment were compared with a group of thirty untreated matched controls, who met the same inclusion criteria. Body weight and the Karnofsky index, which assesses the ability to perform activities of daily life, and several quality-of-life variables were measured to evaluate response to therapy. The average weight gain at peak was 8.2 (SD 6.2) kg (+ 14.5% of body weight at study entry) in the oxymetholone group (P < 0.001), and 6.1 (SD 4.6) kg (+10.9%) in the combination group (P < 0.005), compared with an average weight loss of 1.8 (SD 0.7) kg in the untreated controls. The mean time to peak weight was 19.6 weeks in the monotherapy group and 20.8 weeks in the combination group. The Karnofsky index improved equally in both groups from 56% before to 67% after 20 weeks of treatment (P < 0.05). The quality of life variables (activities of daily life, and appetite/nutrition) improved in 68% (P < 0.05) and 91% (P < 0.01) of the treated patients respectively. Oxymetholone was safe and promoted weight gain in cachectic patients with advanced HIV-1 infection. The addition of ketotifen did not further support weight gain. These results suggest the need for a randomized, double-blind, placebo-controlled multicentre trial.
PMID: 8785183
[PubMed - indexed for MEDLINE]
